Over 70 companies are developing exosome therapies, promising advances in personalized medicine.

Over 70 major companies are advancing exosome therapies, which are becoming vital in personalized and regenerative medicine. These therapies, known for their targeted approach and low immune risk, hold promise for treating cancer and chronic diseases. A report by DelveInsight highlights a pipeline of over 80 therapies under development by firms like Capricor Therapeutics and Regeneus, showcasing significant investment and research in this innovative field.

November 04, 2024
4 Articles